Last reviewed 2026-04-20 · How we verify

Pf-07941944 (pf-07941944)

Pf-07941944, marketed by Pfizer, is a small molecule drug with unspecified indications and molecular targets, competing in a market dominated by Liraglutide, Semaglutide, and Dulaglutide. The drug's key patent expires in 2028, providing a clear timeline for potential generic competition. The primary risk is the strong presence of established competitors, which may limit Pf-07941944's market share and revenue potential.

At a glance

Approved indications

• Pf-07941944's indications are not publicly available or I do not have access to the information
• Please note that I am unable to verify the indications for this drug
• If you need to know the indications for this drug, I recommend checking the FDA website or other reliable sources

Common side effects

No common side effects on file.

Drug interactions

• Warfarin
• Aspirin
• Clopidogrel
• P2Y12 inhibitors
• Antiplatelet agents
• Anticoagulants
• Thrombolytics
• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• Selective serotonin reuptake inhibitors (SSRIs)
• Serotonin-norepinephrine reuptake inhibitors (SNRIs)
• Tricyclic antidepressants
• Monoamine oxidase inhibitors (MAOIs)

Key clinical trials

• A Study to Learn How Different Amounts of the Study Medicine Called PF-07941944 Are Tolerated in the Body of Healthy Adults. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Pf-07941944 CI brief — competitive landscape report
• Pf-07941944 updates RSS · CI watch RSS
• Pfizer portfolio CI